We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Speaker: Dr. Nicolás Fissolo, is senior investigator at the Centre d’Esclerosi Multiple de Catalunya (Cemcat) at the Vall d'Hebron University Hospital in Barcelona. He graduated with a degree in biological chemistry at the University of Córdoba, Argentina in 1999. In 2005, he obtained a Ph.D. in human biology from the University of Ulm, Germany for his work in the DNA vaccine field. Afterwards he carried out a 3-year postdoctoral stage at the Hertie Institute for Clinical Brain Research, in Tübingen, Germany focused in the study of antigen presentation in MS. In 2008, he joined the group of Xavier Montalban, at the Institut de Recerca, Hospital Vall d’Hebron in Barcelona where he is currently working.
Abstract: In the context of multiple sclerosis (MS), the need for objective and measurable indicators of the underlying pathological processes is critical to predict response, disease progression, prognosis and outcome of disease. Therefore, the search for biomarkers, is a continuously expanding field, and a large number of molecules have been explored so far; but only a few have been validated, and even fewer are currently used in clinical practice. In neurological disorders like MS, because of its close proximity to the target organ, the cerebrospinal fluid (CSF) will probably capture better the pathological changes taking place in the central nervous system of MS patients. However, due to the difficulties to access to longitudinal CSF samples to follow-up patient’s progression, it should investigate whether the CSF biomarker is also detected in peripheral blood, serum or plasma, and whether the differences observed in protein abundance in the CSF are also present in blood. In this presentation we will discuss the role of different biomarkers in patients with MS, and we will talk about the transition from CSF to blood guided by the evolution of technologies for biomarker detection.
Host: Dr. Manuel Comabella López, main researcher, group Clinical Neuroimmunology at Vall d’Hebron Research Institute (VHIR)
Register here to attend by Zoom: https://gencat.zoom.us/j/95396181541
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.